<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00675701</url>
  </required_header>
  <id_info>
    <org_study_id>CK-LX1403</org_study_id>
    <nct_id>NCT00675701</nct_id>
  </id_info>
  <brief_title>A Study to Define the ECG Effects of Lixivaptan Compared to Placebo and Moxifloxacin in Healthy Adult Men and Women: A Thorough ECG Study</brief_title>
  <official_title>A Double Blind, Randomized, Repeat-Dose, Parallel Group Study to Define the ECG Effects of Lixivaptan Using a Clinical and a Supratherapeutic Dose, Compared to Placebo and Moxifloxacin (a Positive Control), in Healthy Adult Men and Women: A Thorough ECG Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CardioKine Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cardiokine Biopharma, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>CardioKine Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, double-blind, randomized, repeat-dose, single -dite, 4-arm parallel group&#xD;
      study to define the ECG effect of lixivaptan using a therapeutic and supratherapeutic dose&#xD;
      compared to placebo and moxifloxacin (a positive control in healthy adult men and women.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Timed-matched, placebo-corrected, changed from Baseline in QTc</measure>
    <time_frame>7days</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">298</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo by mouth</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lixivaptan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>moxifloxacin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>capsules</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lixivaptan</intervention_name>
    <description>capsules</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>moxifloxacin</intervention_name>
    <description>tablets</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy males or females, between 18 and 45 years of age, inclusive&#xD;
&#xD;
          2. Body mass index (BMI; see 279HAPPENDIX B) within 18 to 32 kg/m2, inclusive&#xD;
&#xD;
          3. Absence of significant disease as determined by medical history, physical examination,&#xD;
             laboratory evaluations, 12-lead ECG, and vital signs (conducted at Screening or on&#xD;
             admission to the clinic)&#xD;
&#xD;
          4. Normal 12-lead ECG with no clinically significant abnormalities of rate, rhythm, or&#xD;
             conduction (i.e., normal PR interval of 0.12-0.2 sec, normal QRS duration of 0.06-0.1&#xD;
             sec, and a QTc Bazett &lt;440 ms for males or &lt;470 ms for females)&#xD;
&#xD;
          5. Clinical laboratory evaluations (including a serum chemistry panel [fasted at least 8&#xD;
             hours], CBC, and UA) within the reference range for the test laboratory. Laboratory&#xD;
             findings outside the normal reference range may be repeated once; The subject may be&#xD;
             enrolled if laboratory findings outside the normal reference range are deemed not&#xD;
             clinically significant by the investigator&#xD;
&#xD;
          6. Negative test for selected drugs of abuse (280HAPPENDIX A) at Screening and at&#xD;
             Check-in&#xD;
&#xD;
          7. Women must be postmenopausal (more than 12 months since last period, verified by FSH&#xD;
             and estradiol measurements); surgically sterile (hysterectomy or tubal ligation at&#xD;
             least 6 months prior to enrollment); or be using an intrauterine device (including&#xD;
             hormone-impregnated devices), or double barrier (i.e. diaphragm plus spermicide)&#xD;
             non-hormonal contraceptive therapy for the duration of the study; and must have a&#xD;
             negative serum pregnancy test at Screening and Check-in&#xD;
&#xD;
          8. Able to communicate effectively with study personnel&#xD;
&#xD;
          9. Be adequately informed of the nature and risks of the study and able to comprehend and&#xD;
             sign an Informed Consent Form (ICF) prior to any study related procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known hypersensitivity or allergy to lixivaptan (VPA-985), other vasopressin&#xD;
             antagonists, moxifloxacin, or any other fluoroquinolones;&#xD;
&#xD;
          2. Women who are pregnant or breast feeding&#xD;
&#xD;
          3. A first degree relative with Long QT Syndrome or a family history of unexplained&#xD;
             sudden death&#xD;
&#xD;
          4. Any history, disease or condition (medical or surgical) which, in the opinion of the&#xD;
             investigator, might compromise the hematologic, cardiovascular, pulmonary, renal,&#xD;
             gastrointestinal, hepatic, urological, neurological, psychiatric, or central nervous&#xD;
             system; or other conditions that might interfere with the absorption, distribution,&#xD;
             metabolism, or excretion of study drug, or would place the subject at increased risk&#xD;
&#xD;
          5. History of unexplained syncope&#xD;
&#xD;
          6. History of stomach or intestinal surgery or resection that would potentially alter&#xD;
             absorption and/or excretion of orally administered drugs (appendectomy, hernia repair,&#xD;
             and/or cholecystectomy will be allowed)&#xD;
&#xD;
          7. History or presence of an abnormal ECG that, in the Investigator's opinion, is&#xD;
             clinically significant&#xD;
&#xD;
          8. Screening systolic blood pressure &lt;90 mmHg or &gt;140 mmHg, and/or diastolic blood&#xD;
             pressure &gt;90 mmHg&#xD;
&#xD;
          9. Screening heart rate &gt;90 beats per minute&#xD;
&#xD;
         10. Positive screen for hepatitis B (HBsAg), hepatitis C (anti-HCV), or HIV (anti-HIV)&#xD;
&#xD;
         11. Participation in any other investigational study within 30 days prior to Check-in&#xD;
&#xD;
         12. Any history of alcohol abuse, illicit drug use, significant mental illness, physical&#xD;
             dependence to any opioid, or any history of drug abuse or addiction within 6 months&#xD;
             prior to Check-in&#xD;
&#xD;
         13. A history of difficulty with donating blood&#xD;
&#xD;
         14. Donation of â‰¥ 500 mL blood or blood products within 45 days prior to enrollment&#xD;
&#xD;
         15. Receipt of blood products within 2 months prior to Check-in&#xD;
&#xD;
         16. Use of any of the medications in 281HTable 3 within the given timeframe prior to&#xD;
             Check-in:&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site 1</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2008</verification_date>
  <study_first_submitted>May 8, 2008</study_first_submitted>
  <study_first_submitted_qc>May 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2008</study_first_posted>
  <last_update_submitted>June 20, 2011</last_update_submitted>
  <last_update_submitted_qc>June 20, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2011</last_update_posted>
  <responsible_party>
    <name_title>Cardiokine, Ink</name_title>
    <organization>Cardiokine Biopharma, LLC</organization>
  </responsible_party>
  <keyword>To determine whether lixivaptan administration at supratherapeutic or therapeutic doses results in the prolongation of the QTc interval.</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

